Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841265 | 1.00 | MEN1 (0.39) | MEN1KMT2ANPSR1KDM4EMAPT | |
| SCHEMBL4841905 | 0.92 | ALDH1A1 (0.35) | MEN1KMT2ANPSR1KDM4EMAPT | |
| SCHEMBL4840837 | 0.92 | ALDH1A1 (0.35) | MEN1KMT2ANPSR1KDM4EMAPT | |
| SCHEMBL4833527 | 0.90 | NPSR1 (0.32) | MEN1KMT2ANPSR1MAPTRECQL | |
| SCHEMBL4841625 | 0.90 | NPSR1 (0.32) | MEN1KMT2ANPSR1MAPTRECQL | |
| SCHEMBL4833768 | 0.85 | XIAP (0.33) | ALDH1A1SIGMAR1 | |
| SCHEMBL4833359 | 0.85 | XIAP (0.33) | ALDH1A1SIGMAR1 | |
| SCHEMBL4834185 | 0.85 | XIAP (0.33) | ALDH1A1SIGMAR1 | |
| SCHEMBL4838169 | 0.84 | KMT2A (0.33) | MEN1KMT2ANPSR1KDM4E | |
| SCHEMBL4837715 | 0.84 | KMT2A (0.33) | MEN1KMT2ANPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342007-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | claimed |
| US-20060183732-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-08-17 | — | — | US | claimed |
| US-7342007-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| US-20060183732-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-08-17 | — | — | US | disclosed |
| EP-1636196-A1 | NOVEL LACTAMS AND USES THEREOF | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004080983-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183732-A1 | Novel lactams and uses thereof | BACE1, BACE2, APP | MEN1 1456/4885KMT2A 4366/4885NPSR1 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.